Further stratification of HBCV-HCC by the presence or absence of integrated HBV DNA did not reveal significant differences in mutation rates in the TERT promoter (41% vs. 45%, P = 0.6938), CTNNB1 (37% vs. 33%, P = 0.6941), and TP53 (29% vs. 19%, P = 0.2490). This evidence concerns the gene TP53 and hepatocellular carcinoma.